{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:57:09Z","timestamp":1790193429054,"version":"4.1.0"},"reference-count":90,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Liver cirrhosis is a chronic progressive disease marked by the transition from a compensated to a decompensated stage, associated with severe complications. Central to this progression is portal hypertension, which results from increased intrahepatic vascular resistance and endothelial dysfunction, as well as splanchnic vasodilation and an augmented circulatory state. Non-selective beta-blockers (NSBBs) remain the standard of care for portal hypertension, reducing portal pressure by lowering cardiac output via beta-1 receptor blockade and decreasing splanchnic blood flow through beta-2 receptor antagonism. However, clinical application of NSBBs is often hindered by adverse effects such as bradycardia, hypotension, and fatigue, alongside inconsistent efficacy in certain patient populations. Such limitations have driven the search for alternative therapeutic strategies and effective biomarkers for identifying non-responders. Beta-3 adrenergic receptor agonists have emerged as promising candidates, acting through distinct mechanisms, different from NSBBs. By stimulating nitric oxide release from endothelial cells, beta-3 agonists induce selective vasodilation without negatively impacting cardiac function, potentially overcoming the limitations of traditional therapies. This review discusses the molecular pathways of NSBBs, their clinical role and limitations, introduces potential novel biomarkers, and highlights the growing evidence supporting beta-3 receptor agonists as novel and targeted treatments for portal hypertension.<\/jats:p>","DOI":"10.3390\/life15081173","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T09:05:12Z","timestamp":1753347912000},"page":"1173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancements in Beta-Adrenergic Therapy and Novel Personalised Approach for Portal Hypertension: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6956-6686","authenticated-orcid":false,"given":"Raluca-Ioana","family":"Avram","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-8140","authenticated-orcid":false,"given":"Horia Octav","family":"Minea","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huiban","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana-Roxana","family":"Damian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Cornelia","family":"Muset","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Juncu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-5961","authenticated-orcid":false,"given":"Cristina Maria","family":"Muzica","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-3980","authenticated-orcid":false,"given":"Sebastian","family":"Zenovia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-548X","authenticated-orcid":false,"given":"Ana Maria","family":"Singeap","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-1232","authenticated-orcid":false,"given":"Irina","family":"Girleanu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Stanciu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-5520","authenticated-orcid":false,"given":"Anca","family":"Trifan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSt. Spiridon\u201d University Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"ref_1","first-page":"1359","article-title":"Liver cirrhosis","volume":"3981","author":"Krag","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cgh.2021.10.036","article-title":"Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999\u20132018","volume":"21","author":"Griffin","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"GBD US Health Disparities Collaborators (2024). The burden of cirrhosis mortality by county, race, and ethnicity in the USA, 2000\u20132019: A systematic analysis of health disparities. Lancet Public Health, 9, e551\u2013e563.","DOI":"10.1016\/S2468-2667(24)00131-2"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.14680","article-title":"Factors associated with health-related quality of life in patients with cirrhosis: A systematic review","volume":"41","author":"Rabiee","year":"2021","journal-title":"Liver Int."},{"key":"ref_7","first-page":"2689","article-title":"Neuroimmunomodulation of Adrenoblockers during Liver Cirrhosis: Modulation of Hepatic Stellate Cell Activity","volume":"24","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fei, B., Zhao, Y., Wang, J., Wen, P., Li, J., Tanaka, M., Wang, Z., and Li, S. (2024). Leveraging Adrenergic Receptor Blockade for Enhanced Nonalcoholic Fatty Liver Disease Treatment via a Biomimetic Nanoplatform. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02864-z"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sauerbruch, T., Hennenberg, M., Trebicka, J., and Schierwagen, R. (2023). Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1100966"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.17380","article-title":"Review article: Controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis","volume":"57","author":"Gillespie","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2019.09.004","article-title":"Health-related quality of life in patients with compensated and decompensated liver cirrhosis","volume":"70","author":"Labenz","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: From pathophysiology to novel therapeutics","volume":"26","author":"Gunarathne","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pcad.2016.10.005","article-title":"Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well","volume":"59","author":"Frishman","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","article-title":"Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jhep.2022.12.005","article-title":"Beta-blockers in the era of precision medicine in patients with cirrhosis","volume":"78","author":"Albillos","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000462974","article-title":"Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis","volume":"54","author":"Sacerdoti","year":"2017","journal-title":"J. Vasc. Res."},{"key":"ref_18","first-page":"S27","article-title":"The Concise Guide to Pharmacology 2021\/22: G protein-coupled receptors","volume":"178","author":"Alexander","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_19","unstructured":"Alhayek, S., and Preuss, C.V. (2023). Beta 1 Receptors. StatPearls, StatPearls Publishing."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.amjms.2024.01.009","article-title":"Beta-blockers and cirrhosis: Striking the right balance","volume":"367","author":"Cromer","year":"2024","journal-title":"Am. J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl230072","article-title":"Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease","volume":"18","author":"Kotani","year":"2024","journal-title":"Gut Liver"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","volume":"43","author":"Turco","year":"2023","journal-title":"Liver Int."},{"key":"ref_23","first-page":"02772","article-title":"Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis","volume":"S0168-8278","author":"Fortea","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2017.02.005","article-title":"Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites","volume":"67","author":"Sinha","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_25","first-page":"CD011510","article-title":"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices","volume":"10","author":"Zacharias","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","first-page":"100063","article-title":"Beta-blockers in cirrhosis: Evidence-based indications and limitations","volume":"1","author":"Rodrigues","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol-IPD-MA-group and the Baveno Cooperation: An EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12072-016-9765-y","article-title":"Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT","volume":"11","author":"Gupta","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.510300124","article-title":"Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis","volume":"30","author":"Moitinho","year":"1999","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/hep.1840360612","article-title":"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis","volume":"36","author":"Moitinho","year":"2002","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2036.2002.01190.x","article-title":"Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension","volume":"16","author":"Tripathi","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: The haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bond, R.A., Lucero Garcia-Rojas, E.Y., Hegde, A., and Walker, J.K.L. (2019). Therapeutic Potential of Targeting \u00df-Arrestin. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00124"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4254\/wjh.v14.i2.429","article-title":"\u03b2-arrestin-2 predicts the clinical response to \u03b2-blockers in cirrhotic portal hypertension patients: A prospective study","volume":"14","author":"Lashen","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2016.01.022","article-title":"Assessment of response to beta-blockers by expression of \u03b2Arr2 and RhoA\/ROCK2 in antrum mucosa in cirrhotic patients","volume":"64","author":"Trebicka","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1073\/pnas.1922608117","article-title":"\u03b2-Arrestin2 is a critical component of the GPCR-eNOS signalosome","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2015.02.015","article-title":"Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study","volume":"184","author":"Lin","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1940-6207.CAPR-17-0132","article-title":"Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis","volume":"10","author":"Huang","year":"2017","journal-title":"Cancer Prev. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cheng, H.Y., Lin, H.C., Lin, H.L., Uang, Y.S., Keller, J.J., and Wang, L.H. (2022). Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Without Cirrhosis and Decompensation. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.805318"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chang, P.Y., Chung, C.H., Chang, W.C., Lin, C.S., Lin, H.H., Dai, M.S., Ho, C.L., and Chien, W.C. (2019). The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216828"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jhep.2023.05.048","article-title":"Selection of patients with portal hypertension and cirrhosis who will benefit from beta-blockers: Still a current challenge","volume":"80","author":"Santos","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eade4335","DOI":"10.1126\/scisignal.ade4335","article-title":"The heavy subunit of ferritin stimulates NLRP3 inflammasomes in hepatic stellate cells through ICAM-1 to drive hepatic inflammation","volume":"17","author":"Pearen","year":"2024","journal-title":"Sci. Signal"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Almenara, S., Lozano-Ruiz, B., Herrera, I., Gimenez, P., Miralles, C., Bellot, P., Rodriguez, M., Palazon, J.M., Tar\u00edn, F., and Sarmiento, H. (2023). Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study. Biomed. Pharmacother., 163.","DOI":"10.1016\/j.biopha.2023.114885"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","article-title":"ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis","volume":"108","author":"Bui","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hintermann, E., and Christen, U. (2019). The Many Roles of Cell Adhesion Molecules in Hepatic Fibrosis. Cells, 8.","DOI":"10.3390\/cells8121503"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","article-title":"Cirrhosis-associated immune dysfunction","volume":"19","author":"Albillos","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1177\/1535370220949148","article-title":"Endothelin-1 in portal hypertension: The intricate role of hepatic stellate cells","volume":"245","author":"Ezhilarasan","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.29328\/journal.ascr.1001081","article-title":"Non-invasive Serological Markers of Hepatic Fibrosis\u2014Mini Review","volume":"8","author":"Popa","year":"2024","journal-title":"Arch. Surg. Clin. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cyto.2015.05.025","article-title":"Endothelin 1 and transforming growth factor-\u03b21 correlate with liver function and portal pressure in cirrhotic patients","volume":"76","author":"Siemiatkowski","year":"2015","journal-title":"Cytokine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jceh.2023.05.016","article-title":"Von Willebrand Factor as a Biomarker for Liver Disease\u2014An Update","volume":"13","author":"Elhence","year":"2023","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.dld.2022.06.010","article-title":"Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease","volume":"54","author":"Pomej","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100368","DOI":"10.1016\/j.jhepr.2021.100368","article-title":"Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis","volume":"3","author":"Villanueva","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_57","first-page":"309","article-title":"Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature","volume":"5","author":"Manicardi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1665-2681(19)31362-6","article-title":"Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease","volume":"12","author":"Matilla","year":"2013","journal-title":"Ann. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A Calcium Antagonist vs a Non\u2013Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fasolato, S., Bonaiuto, E., Rossetto, M., Vanzani, P., Ceccato, F., Vittadello, F., Zennaro, L., Rigo, A., Mammano, E., and Angeli, P. (2024). Serum Vascular Adhesion Protein-1 and Endothelial Dysfunction in Hepatic Cirrhosis: Searching for New Prognostic Markers. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137309"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s43066-023-00268-6","article-title":"Validity of serum resistin level and Il-6 as prognostic biomarkers of decompensated liver cirrhosis in chronic hepatitis C virus patients","volume":"13","author":"Degheidy","year":"2023","journal-title":"Egypt Liver J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cyto.2018.10.024","article-title":"The imbalance of peripheral interleukin-18 and transforming growth factor-\u03b21 levels in patients with cirrhosis and esophageal varices","volume":"113","author":"Siemiatkowska","year":"2019","journal-title":"Cytokine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.cgh.2021.07.012","article-title":"Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death","volume":"20","author":"Jachs","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12257-021-0036-y","article-title":"Loss of ADAMTS15 Promotes Browning in 3T3-L1 White Adipocytes via Activation of \u03b23-adrenergic Receptor","volume":"26","author":"Choi","year":"2021","journal-title":"Biotechnol. Bioproc. E"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.3748\/wjg.v21.i23.7191","article-title":"\u03b2-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis","volume":"21","author":"Kong","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jgh.13198","article-title":"Influence of CYP2D6 and \u03b22-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","article-title":"Pharmacogenetic factors affecting \u03b2-blocker metabolism and response","volume":"16","author":"Thomas","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41397-021-00257-1","article-title":"Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking \u03b2-blockers","volume":"22","author":"Guerra","year":"2022","journal-title":"Pharmacogenom. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/17474124.2023.2215428","article-title":"Beta-adrenergic blockade in cirrhosis\u2014Harmful or helpful?","volume":"17","author":"Danielsen","year":"2023","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Pasha, A., Tondo, A., Favre, C., and Calvani, M. (2024). Inside the Biology of the \u03b23-Adrenoceptor. Biomolecules, 14.","DOI":"10.3390\/biom14020159"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Schena, G., and Caplan, M.J. (2019). Everything You Always Wanted to Know about \u03b23-AR * (* But Were Afraid to Ask). Cells, 8.","DOI":"10.3390\/cells8040357"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/poh2.27","article-title":"The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient","volume":"1","author":"Wortham","year":"2022","journal-title":"Portal Hypertens. Cirrhosis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1476-5381.2012.02074.x","article-title":"Portal hypertension and liver cirrhosis in rats: Effect of the \u03b23-adrenoceptor agonist SR58611A","volume":"167","author":"Vasina","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u226565 yr with overactive bladder wet: A phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e14321","DOI":"10.1111\/acel.14321","article-title":"Chronic \u03b23-AR stimulation activates distinct thermogenic mechanisms in brown and white adipose tissue and improves systemic metabolism in aged mice","volume":"23","author":"Natarajan","year":"2024","journal-title":"Aging Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"939","DOI":"10.14218\/JCTH.2022.00067","article-title":"Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD","volume":"10","author":"Clare","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"Engelmann","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"Metabolic dysfunction\u2013associated fatty liver disease (MAFLD): An update of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4103\/JCMRP.JCMRP_40_19","article-title":"Hepatoprotective and antiobesity effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on carbon tetrachloride-induced hepatotoxicity in obese rats","volume":"5","author":"Elbadr","year":"2020","journal-title":"J. Curr. Med. Res. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10020-020-00164-4","article-title":"The protective effects of the \u03b23 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD)","volume":"26","author":"Wang","year":"2020","journal-title":"Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"168167","DOI":"10.1016\/j.scitotenv.2023.168167","article-title":"\u03b23 adrenergic receptor activation alleviated PM2.5-induced hepatic lipid deposition in mice","volume":"907","author":"Gu","year":"2023","journal-title":"Sci. Total Environ."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Bassal, T., Basheer, M., Boulos, M., and Assy, N. (2022). Nonalcoholic Fatty Liver Disease\u2014A Concise Review of Noninvasive Tests and Biomarkers. Metabolites, 12.","DOI":"10.3390\/metabo12111073"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4254\/wjh.v7.i3.443","article-title":"Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress","volume":"7","author":"Vairappan","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"979","DOI":"10.14218\/JCTH.2021.00593","article-title":"Portal Hypertension in Nonalcoholic Fatty Liver Disease: From Pathogenesis to Clinical Practice","volume":"10","author":"Nababan","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bcpt.13319","article-title":"The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase","volume":"127","author":"Golshiri","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Potocka, N., Skrzypa, M., Zadarko-Domaradzka, M., Barabasz, Z., Penar-Zadarko, B., Sakowicz, A., Zadarko, E., and Zawlik, I. (2023). Effects of the Trp64Arg Polymorphism in the ADRB3 Gene on Body Composition, Cardiorespiratory Fitness, and Physical Activity in Healthy Adults. Genes, 14.","DOI":"10.3390\/genes14081541"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Evans, C.J.F., Glastras, S.J., Tang, O., and Figtree, G.A. (2023). Therapeutic Potential for Beta-3 Adrenoreceptor Agonists in Peripheral Arterial Disease and Diabetic Foot Ulcers. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123187"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, A., Ye, M., and Zhang, C. (2024). Examining the safety of mirabegron: An analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1376535"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/8\/1173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:15:03Z","timestamp":1760033703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/8\/1173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":90,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["life15081173"],"URL":"https:\/\/doi.org\/10.3390\/life15081173","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}